{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:23:38Z","timestamp":1768875818160,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.annder.2020.08.043","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T10:20:21Z","timestamp":1603189221000},"page":"848-852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Alop\u00e9cie cicatricielle \u00e0 type de folliculite d\u00e9calvante induite par l\u2019erlotinib"],"prefix":"10.1016","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8726-0969","authenticated-orcid":false,"given":"C.","family":"Dervout","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-M.","family":"Chiappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fleuret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Plantin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Acquitter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2020.08.043_bib0115","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4103\/0378-6323.157448","article-title":"Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99\u00a0cases","volume":"81","author":"Chanprapaph","year":"2015","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.annder.2020.08.043_bib0120","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.08.043_bib0125","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1529-8019.2008.00204.x","article-title":"Folliculitis decalvans","volume":"21","author":"Otberg","year":"2008","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.annder.2020.08.043_bib0130","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jaad.2018.07.050","article-title":"Updates in therapeutics for folliculitis decalvans: a systematic review with evidence-based analysis","volume":"80","author":"Rambhia","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.08.043_bib0135","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jaad.2015.02.1120","article-title":"Treatment of folliculitis decalvans with photodynamic therapy: results in 10\u00a0patients","volume":"72","author":"Miguel-Gomez","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.08.043_bib0140","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jaad.2018.05.1240","article-title":"Folliculitis decalvans: Effectiveness of therapies and prognostic factors in a multicenter series of 60\u00a0patients with long-term follow-up","volume":"79","author":"Miguel-G\u00f3mez","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.08.043_bib0145","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4103\/ijt.ijt_34_18","article-title":"A Case of Isotretinoin Therapy-Refractory Folliculitis Decalvans Treated Successfully with Biosimilar Adalimumab (Exemptia)","volume":"10","author":"Shireen","year":"2018","journal-title":"Int J Trichology"},{"key":"10.1016\/j.annder.2020.08.043_bib0150","first-page":"589","article-title":"Successful use of infliximab in a patient with recalcitrant folliculitis decalvans","volume":"10","author":"Mihaljevi\u0107","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.annder.2020.08.043_bib0155","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/ced.12083","article-title":"Erlotinib-induced folliculitis decalvans","volume":"38","author":"Keith","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2020.08.043_bib0160","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ad.2017.02.032","article-title":"Foliculitis decalvante por sobreinfecci\u00f3n bacteriana secundaria a erlotinib","volume":"109","author":"Sahuquillo-Torralba","year":"2018","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"10.1016\/j.annder.2020.08.043_bib0165","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1365-2230.2010.03852.x","article-title":"Folliculitis decalvans associated with erlotinib: Correspondence","volume":"35","author":"Hoekzema","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2020.08.043_bib0170","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.5021\/ad.2011.23.S3.S350","article-title":"A case of cicatricial alopecia associated with erlotinib","volume":"23","author":"Yang","year":"2011","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.annder.2020.08.043_bib0175","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/JTO.0b013e31815ba7f9","article-title":"Erlotinib-associated alopecia in a lung cancer patient","volume":"2","author":"Costa","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.annder.2020.08.043_bib0180","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jaad.2009.08.024","article-title":"Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib","volume":"64","author":"Hepper","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.08.043_bib0185","first-page":"70","article-title":"Erlotinib-induced scalp perifolliculitis","volume":"10","author":"Rallis","year":"2012","journal-title":"Skinmed"},{"key":"10.1016\/j.annder.2020.08.043_bib0190","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000341528","article-title":"Erosive pustular dermatosis of the scalp-like eruption due to gefitinib: case report and review of the literature of alopecia associated with EGFR inhibitors","volume":"225","author":"Toda","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2020.08.043_bib0195","first-page":"1959","article-title":"Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development","volume":"150","author":"Hansen","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.annder.2020.08.043_bib0200","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1600-0560.2009.01275.x","article-title":"A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib","volume":"36","author":"Pongpudpunth","year":"2009","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.annder.2020.08.043_bib0205","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/exd.13916","article-title":"Folliculitis decalvans is characterized by a persistent, abnormal subepidermal microbiota","volume":"29","author":"Matard","year":"2020","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.annder.2020.08.043_bib0210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/djp439","article-title":"Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy","volume":"102","author":"Eilers","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.annder.2020.08.043_bib0215","first-page":"3943","article-title":"EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections","volume":"24","author":"Braden","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annder.2020.08.043_bib0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-4632.2011.05082.x","article-title":"The management of EGFR inhibitor adverse events: a case series and treatment paradigm","volume":"51","author":"Wnorowski","year":"2012","journal-title":"Int J Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963820303975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963820303975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:10:13Z","timestamp":1758971413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963820303975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0151963820303975"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2020.08.043","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alop\u00e9cie cicatricielle \u00e0 type de folliculite d\u00e9calvante induite par l\u2019erlotinib","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2020.08.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}